KANEKO, AKIHISA,金子晃久,IWAYANAGI, YUKI,岩柳有起,KITAMURA, HIDETOMO,北村秀智,HIGUCHI, YOSHINOBU,樋口义信,樋口義信,MATSUSHITA, HIROAKI,松下浩明,MIHARA, RYOSUKE,三原良介,YAMAMOTO, YUMI,山本裕美,SAITO, TO
申请号：
TW105111451
公开号：
TW201642905A
申请日:
2016.04.13
申请国别(地区):
TW
年份:
2016
代理人:
摘要：
In a non-limiting embodiment, a pharmaceutical composition for the prevention and/or treatment of atopic dermatitis is provided, the pharmaceutical composition containing an IL-31 antagonist as an active ingredient, wherein 0.1-1000 mg/body/1 day-12 weeks, preferably 0.1-1000 mg/body/2 weeks, 0.1-1000 mg/body/4 weeks, or 0.1-1000 mg/body/8 weeks, of the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject who has contracted or is at risk for contracting atopic dermatitis.於一非限定的實施態樣，提供一種含有IL-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物，前述IL-31拮抗劑係以0.1mg~1000mg/body/1日~12週，較佳為0.1mg~1000mg/body/2週、0.1mg~1000mg/body/4週、或0.1mg~1000mg/body/8週，對於罹患異位性皮膚炎、或有罹患異位性皮膚炎之風險之對象以等量且相同投予間隔重複投予。
